Tianjin Development (00882): Tianjin Lisheng Pharmaceutical Reports 3.71 Billion Yuan Net Profit for the First Three Quarters, Up 119.05% Year-on-Year

Stock News

10/24

According to an announcement from Tianjin Development (00882), its indirectly held subsidiary, Tianjin Lisheng Pharmaceutical Co., Ltd. (Lisheng Pharmaceutical), reported total operating revenue of 1.007 billion yuan for the nine months ending September 30, 2025, a year-on-year decrease of 1.61%. The net profit attributable to shareholders of the parent company was 371 million yuan, marking a significant year-on-year increase of 119.05%. The basic earnings per share amounted to 1.44 yuan.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1106698407"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1106698407\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1106698407?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-24 06:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106698407","market":"hk","top_or_hot":-1,"title":"Tianjin Development (00882): Tianjin Lisheng Pharmaceutical Reports 3.71 Billion Yuan Net Profit for the First Three Quarters, Up 119.05% Year-on-Year","media":"Stock News","content":"<p>According to an announcement from Tianjin Development (00882), its indirectly held subsidiary, Tianjin Lisheng Pharmaceutical Co., Ltd. (Lisheng Pharmaceutical), reported total operating revenue of 1.007 billion yuan for the nine months ending September 30, 2025, a year-on-year decrease of 1.61%. The net profit attributable to shareholders of the parent company was 371 million yuan, marking a significant year-on-year increase of 119.05%. The basic earnings per share amounted to 1.44 yuan.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tianjin Development (00882): Tianjin Lisheng Pharmaceutical Reports 3.71 Billion Yuan Net Profit for the First Three Quarters, Up 119.05% Year-on-Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTianjin Development (00882): Tianjin Lisheng Pharmaceutical Reports 3.71 Billion Yuan Net Profit for the First Three Quarters, Up 119.05% Year-on-Year\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2025-10-24 06:18</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>According to an announcement from Tianjin Development (00882), its indirectly held subsidiary, Tianjin Lisheng Pharmaceutical Co., Ltd. (Lisheng Pharmaceutical), reported total operating revenue of 1.007 billion yuan for the nine months ending September 30, 2025, a year-on-year decrease of 1.61%. The net profit attributable to shareholders of the parent company was 371 million yuan, marking a significant year-on-year increase of 119.05%. The basic earnings per share amounted to 1.44 yuan.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"002393","symbol_name":"力生製藥","start_time":0,"source_url":"","article_id":"1106698407","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106698407","pubTimestamp":1761257889,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"According to an announcement from Tianjin Development (00882), its indirectly held subsidiary, Tianjin Lisheng Pharmaceutical Co., Ltd. (Lisheng Pharmaceutical), reported total operating revenue of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"002393":"力生制药","BK0028":"国家队","00882":"天津发展","BK0239":"医药制造","BK1232":"复合型公用事业","BK0188":"融资融券"},"translate_title":"天津发展(00882)：天津力生制药报前三季净利37.1亿元同比增119.05%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002393":1,"00882":1},"content_text":"According to an announcement from Tianjin Development (00882), its indirectly held subsidiary, Tianjin Lisheng Pharmaceutical Co., Ltd. (Lisheng Pharmaceutical), reported total operating revenue of 1.007 billion yuan for the nine months ending September 30, 2025, a year-on-year decrease of 1.61%. The net profit attributable to shareholders of the parent company was 371 million yuan, marking a significant year-on-year increase of 119.05%. The basic earnings per share amounted to 1.44 yuan.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}